Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN
07/27 ABARCA HEALTH : And Biogen Announces Innovative Value-Based Contract For Multipl..
07/27 BIOGEN : Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem..
07/27 BIOGEN : Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Ann..
07/25 BIOGEN : Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Rev..
07/25 BIOGEN : Investor Network: Biogen Inc. to Host Earnings Call
07/24 BIOGEN : Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operati..
07/14 BIOGEN : to Present Data at Alzheimer's Association International Conference® 20..
07/10 BIOGEN : Appoints Amy Chevalier Efantis Vice President of Government Affairs
06/28 BIOGEN : Appoints Catherine Steele Senior Vice President of Corporate Affairs
06/23 BIOGEN : IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Grant..
More news
News from SeekingAlpha
07/26 BIOGEN Q2 2017 RESULTS : Few Steps In The Right Direction
07/26 Biogen Positions Itself For The Future
07/26 2 Cheers For Biogen, Which May Be Good Enough To Allow Alpha
07/25 Nektar Makes A Stride Forward In Resolving Autoimmune Diseases
07/25 Samsung Leaps Into Its First U.S. Biosimilars Battle
Financials ($)
Sales 2017 11 816 M
EBIT 2017 6 128 M
Net income 2017 3 878 M
Debt 2017 1 684 M
Yield 2017 -
P/E ratio 2017 15,97
P/E ratio 2018 13,54
EV / Sales 2017 5,29x
EV / Sales 2018 4,91x
Capitalization 60 882 M
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 328 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Gregory F. Covino VP-Finance, Chief Financial & Accounting Officer
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Adriana Karaboutis Executive VP-Technology & Business Solutions
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN10.18%62 501
CSL LIMITED29.48%46 735
ALEXION PHARMACEUTICALS9.46%29 433
GRIFOLS SA21.72%16 773
BIOMARIN PHARMACEUTICAL5.41%15 565
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%4 457